Market News
- Sanders takes aim at US drug prices of Novo’s Ozempic and Wegovyby Justine Ra (Pharmaceutical Technology) on April 25, 2024
A Senate Committee is investigating the “outrageously high” US price tags of the blockbuster diabetes and obesity drugs.
- AstraZeneca’s earnings surprise investors as cancer drugs fuel growthby Jonathan Gardner (BioPharma Dive – Latest News) on April 25, 2024
The British drugmaker has bolstered its business with nearly $5 billion in acquisitions as attention turns to its pipeline of experimental medicines.
- Novartis, Medicines for Malaria Venture Release Positive Results from Phase II/III Trial of Coartem for Infants with Malariaby OncLive articles on April 25, 2024
Companies reported that the new formulation of Coartem met required pharmacokinetic profiles and displayed promising efficacy and safety treating malaria in infants.
- FDA Approves Utility Therapeutics’ Pivya to Treat Uncomplicated Urinary Tract Infections in Adult Femalesby OncLive articles on April 25, 2024
Pivya has shown efficacy against bacteria strains such as Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.
- Cidara buys back rights to flu therapy from J&J for $85mby Phalguni Deswal (Pharmaceutical Technology) on April 25, 2024
Marking another chapter in the long-running saga, J&J has deprioritised the CD388 influenza programme allowing Cidara to buy it back.
- Inflation Reduction Act to have knock on effect on R&D, say biotech experts by Jenna Philpott (Pharmaceutical Technology) on April 25, 2024
As the Biden Administration faces lawsuits from pharma companies, industry experts discuss the impact of the Inflation Reduction Act on R&D.
- BioMarin drops drug programs in pipeline cullby Kristin Jensen (BioPharma Dive – Latest News) on April 25, 2024
The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.
- Bernie Sanders Announces Investigation into Ozempic and Wegovy Pricingby OncLive articles on April 25, 2024
Sanders wrote a letter to Novo Nordisk announcing the investigation.
- Crafting Culturally Sensitive Messages to Reach Diverse Audiences and Improve Patient Outcomesby OncLive articles on April 25, 2024
In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but address […]
- Bristol Myers to cut 6% of workforce, trim drug pipelineby Ned Pagliarulo (BioPharma Dive – Latest News) on April 25, 2024
The layoffs will impact some 2,200 employees, the company said, as it repositions ahead of looming patent expirations for top-selling products.
- Podcast #1: Doing Digital Deals in Life Sciences | Corporate Cultureby lawrence (Pharmaceutical Technology) on April 25, 2024
The first episode in Sterling’s podcast series on digital dealmaking in life sciences puts a spotlight on corporate culture
- Howard Berman Discusses Potential Indications for Coya 302by OncLive articles on April 25, 2024
In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides a look into the potential of further indications for Coya 302 amid promising ALS study.
- Regeneron expands in gene editing with Mammoth dealby Gwendolyn Wu (BioPharma Dive – Latest News) on April 25, 2024
“With each passing year, we’re more committed to becoming a serious player in the genetic medicine space,” a Regeneron executive said.
- Merck plans €300m investment at new German research centreby Archana Rani (Pharmaceutical Technology) on April 25, 2024
Merck has announced an investment of more than €300m ($320.8m) in a new Life Science Research Center at its global headquarters in Darmstadt, Germany.
- Mundipharma to acquire rezafungin assets from Cidara Therapeuticsby Archana Rani (Pharmaceutical Technology) on April 25, 2024
Mundipharma is to acquire all assets and rights related to antifungal candidate Rezzayo (rezafungin) from Cidara Therapeutics.
- What Impact is AI Having on the Collection and Analysis of RWE?by OncLive articles on April 25, 2024
AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.
- Pharma Pulse 4/25/24: Meta’s AI Assistant Can’t Be Trusted, Remote Patient Monitoring Analysis Report 2024 & moreby OncLive articles on April 25, 2024
The latest news for pharma industry insiders.
- Life science SMEs “heading out of the funding winter”by Jenna Philpott (Pharmaceutical Technology) on April 25, 2024
Speakers discuss how SMEs can attract capital after a rise in investment activity in Q1 2024 compared to the last quarter of 2023.
- Biogen reports net income of $393.4m in Q1 2024by Archana Rani (Pharmaceutical Technology) on April 25, 2024
Biogen has reported net income of $393.4m for the first quarter (Q1) of 2024, an increase from $387.6m in the same period a year ago.
- FDA approves Utility Therapeutics’ Pivya tablets for UTIsby Archana Rani (Pharmaceutical Technology) on April 25, 2024
The FDA has approved Utility Therapeutics’ Pivya tablets, a new treatment for female adults with UTIs.